Skip to content
Menu

Thermo Fisher Scientific Inc. TMO

Full chart Compare
Set alert

Price alert · TMO

All alert types
669.54 USD -19.21 (-2.79%)

Regular-session close

673.50 +3.96 +0.59%

After hours · Nov 20, 6:41 PM ET

667.95 Day range 692.00
438.34 52-week range 721.63
YTD
+15.55%
1 year
+16.90%

5D -29.98 (-4.28%)

670680690700MonTueWedThuFri671.24
Market cap
248.08B
Revenue (ttm)
47.35B
Profit margin
14.94%
EPS (ttm)
18.96
Shares out
370.52M
P/E ratio
35.31
Forward P/E
24.16
Dividend
1.88 (0.27%)
Ex-dividend date
Dec 15, 2026
YTD return
+15.55%
1-year return
+16.90%
Volume
2.36M
Avg volume
2.14M
Open
689.72
Previous close
688.75
Day's range
667.95 – 692.00
52-week range
438.34 – 721.63
Beta
0.84
Analysts
Strong Buy
Price target
756.52 (+13.0%)
Earnings date
Feb 4, 2027
50-day average
677.30

Key statistics

200-day average
557.69
Enterprise value
290.64B
PEG ratio
2.01
Price / sales
5.25
Price / book
4.54
Payout ratio
9.70%
Revenue growth
9.10%
Free cash flow
6.44B
Total cash
6.06B
Total debt
41.37B
Return on equity
13.38%
Short % of float
1.29%

Fundamental scorecard

14 of 25 checks passed on TMO’s reported financials

ValueGrowthProfitabilityHealthDividend

14of 25 checks passed

  • Value 0 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 3 of 5
  • Dividend 4 of 5

Statements to Sep 26, 2026.

Financials — quick view

All financials
TMO Revenue — quarterly 12.14B
TMO Net income — quarterly 1.72B
TMO EPS — quarterly 4.65

Earnings

TMO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 4, 2027Dec 26, 20267.12———
Oct 21, 2026Sep 26, 20266.406.68+0.28+4.37%
Jul 23, 2026Jun 27, 20265.726.03+0.31+5.42%
Apr 23, 2026Mar 28, 20265.255.44+0.19+3.62%
Jan 29, 2026Dec 31, 20256.456.57+0.12+1.86%
Oct 22, 2025Sep 27, 20255.505.79+0.29+5.27%

Upgrades / downgrades

TMO analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026Argus ResearchmainBuyBuy
Oct 23, 2026CitigroupmainBuyBuy
Oct 22, 2026BarclaysmainOverweightOverweight
Oct 22, 2026RBC CapitalmainSector PerformSector Perform
Oct 22, 2026TD CowenmainBuyBuy
Oct 22, 2026StifelmainBuyBuy

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on TMO — it syncs with the Stock Master app.

Insider holders

TMO insider holders
InsiderRelationLatest transactionDateShares held
BOXER MICHAEL AGeneral CounselSaleMar 9, 202510,815
BRITT LISA POfficerSaleAug 18, 202614,784
CASPER MARC NChief Executive OfficerSaleAug 23, 2026140,225
CHAI NELSON JDirectorStock Award(Grant)May 19, 202615,316
LAGARDE MICHELChief Operating OfficerStock Award(Grant)Feb 24, 202686,347
LOWERY FREDERICK M.OfficerStock Award(Grant)Feb 24, 202617,133

Institution ownership

TMO institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.68%32,167,48521.59BSep 29, 2026
Vanguard Capital Management LLC6.53%24,206,14416.25BSep 29, 2026
FMR, LLC5.98%22,173,79214.88BSep 29, 2026
State Street Corporation4.56%16,892,59211.34BSep 29, 2026
Morgan Stanley2.84%10,518,3407.06BSep 29, 2026
JPMORGAN CHASE & CO2.82%10,437,6817.01BSep 29, 2026

Fund ownership

TMO fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%11,797,8007.92BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.60%9,628,7136.46BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%4,926,5073.31BSep 29, 2026
Fidelity Contrafund1.33%4,919,7043.30BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%4,805,2163.23BSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.23%4,572,5553.07BSep 29, 2026